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Editorial
The pseudo-high-risk prevention strategy
Some 30 years ago, the strengths and weaknesses of popu-
lation-based and high-risk prevention strategies were bril-
liantly delineated by Geoffrey Rose in several seminal
publications (Table 1).1,2 His work had major implications
not only for epidemiology and public health but also for
clinical medicine. In particular, Rose demonstrated the
fundamental failure of high-risk prevention strategies, that
is, by missing a large number of preventable cases.1 Indeed,
since most cases of diseases do not originate among indi-
viduals within the highest risk category, the high-risk pre-
vention strategies fail to prevent diseases in the numerous
individuals at a small but non-optimal risk and from
whom originates a large, if the not the largest, number of
cases (Figure 1).
For Rose, this failure of high-risk prevention strategies
was a strong argument in favour of population-based
prevention strategies which are designed ‘to control the
determinants of incidence, to lower the mean level of
risk factors, [and] to shift the whole distribution of
exposure in a favourable direction’1 and, hence, to reduce
the risk in all segments of the population. That was
however not an argument to target a larger number of
individuals for individualized high-risk prevention
strategies.
From this viewpoint, we argue that the development
of individual predictive medicine and the widening of
high-risk categories for numerous (chronic) conditions
are fundamentally at odds with Rose’s arguments and lead
to the application of pseudo-high-risk prevention
strategies.
High-risk vs population-based
prevention strategies
Population-based prevention strategies aim to shift the whole
distribution of risk factors toward ideal values (Table 1).1,2
Their rational is based notably on the continuum in the rela-
tion between the level of many risk factors and the absolute
risk of disease (Figure 1). They are relevant because, at a
population level, most cases of diseases occur in individuals
with risk factors not in the highest risk category of diseases.
More precisely, notably for cardiovascular diseases, most
cases occur in individuals with levels of risk factors around
the population average, where most people are found if risk
factors are normally distributed.
Population-based strategies require mass (structural)
interventions reaching the entire population and targeting
the determinant of average risk.3,4 One advantage is that
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Table 1. Principles, strengths and weaknesses of each preventive strategy (adapted from Rose 19851 and Rose 19922)
Population-based High-risk Pseudo-high-riskPrinciple
Shift the whole risk distri-
bution toward lower risk
values
Identify and treat individ-
uals at the highest risk of
disease
Identify and treat individ-
uals at intermediate and
high risk of disease
Global efficacy Radical Palliative and temporary Palliative and temporary
Potential benefit for populations Large Small Small
Potential benefit for individuals Small Large Large for some, small for
many
Behaviourally appropriate Yes No No
Motivation for patients and physicians Small Large Large
Balance risk/benefit Worrisome if the interven-
tion causes some harms
Good unless the interven-
tion causes major harms
Good for some, worrisome
for many
Issues of thresholds definition, risk
stratification and screening/diagnostic tests
No Yes Yes
Level of 
risk factor
Absolute 
risk of 
disease
*
**
Frequency
Frequency
Frequency
D
A
B
C
Figure 1. A) Population-based prevention strategies aim at shifting the whole distribution of risk factors toward lower values; B) High-risk prevention
strategies aim at treating the individuals at the highest risk in the population; C) Pseudo-high-risk strategies aim at treating the individuals at inter-
mediate and high risk in the population; D) The line shows the log-linear relationship often observed between a risk factor and the absolute risk of the
disease.10 A change in the level of risk factor for individuals within the high-risk range (*) is associated with a substantial change in the absolute risk
of disease. By contrast, a similar change in the level of risk factor for individuals within the intermediate-risk range (**) is associated with a small
change in the absolute risk of disease.
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they do not require screening and individual diagnostic tests
or any stratification methods to estimate risk. Nevertheless,
as the individual benefit is often small, the risk of the
intervention has to be minimal for the population-based
strategies to have a favourable benefit/harm ratio.4
High-risk prevention strategies consist in the identifica-
tion and treatment of individuals at the highest risk of
disease (Table 1 and Figure 1).1 One difficulty of these strat-
egies is that they require tools to identify these individuals
by appropriate screening and diagnostic tests and by stratifi-
cation methods. Hence, resources have to be devoted to the
assessment of risk.4 High-risk strategies are the standard ap-
proach for clinicians and necessitate the participation of in-
dividuals. It can be however very hard even for high-risk
individuals to make appropriate behaviour changes, espe-
cially if the environment is not optimal to do so and, if
treated, to adhere to medications, especially to prevent a
hypothetical and remote chronic condition.
Principles, strengths and weaknesses of both types of
prevention strategies are listed in Table 1 and have been
discussed extensively.4–7
Absolute risk prediction and individual
predictive medicine
A specificity of high-risk strategies is that they require ac-
curate methods and valid data, first to predict the absolute
risk of future disease and second, to discriminate with con-
fidence the individuals having a high probability of disease
from those having a low probability of disease.3 However,
accurate prediction is very difficult, especially for chronic
conditions. Indeed, chronic conditions such as cardiovas-
cular diseases or cancers are characterized by a long
preclinical period, with a slow pathological process over
many decades, leading eventually to the clinically apparent
disease. This process is complex, affected by numerous
factors and dynamic: it does not always show regular pro-
gression and can be interrupted, if not reversed.
Despite this complexity, during the preclinical period it
is possible to identify early risk markers of disease, which
are either true early forms of the disease (e.g. precancerous
lesions), surrogates (e.g. arterial stiffness) or merely (causal
or non-causal) risk factors (e.g. blood pressure). Prediction
tools to estimate the absolute risk of disease are based on
the identification of these markers and on the design of ap-
propriate algorithms to estimate risk. These tools are
highly heterogeneous in their conception and are used in
different settings: some are based on self-reported measures,
others on clinical information and others on highly detailed
biological information, such as genetic information.8,9 They
are the constitutive elements of the ever growing field of in-
dividual predictive medicine or personalized medicine. In an
ideal setting, these tools should be able to discriminate fu-
ture cases from non-cases, they should be calibrated on the
absolute risk of the targeted population and they should
help reclassify individuals in the proper risk strata. Not all
these tools are focused on individual risk assessment and, in
several specific clinical situations, some are useful.
However, most of the existing prediction tools are in-
capable predicting the absolute risk for instance of cardio-
vascular diseases at an individual level. Although they can
estimate with accuracy the probability of having a disease
at the population or group level, they cannot identify
which individuals will actually develop the disease.10,11
Research in personalized (e.g. omics-based) medicine may
improve individualized prediction and increase discrimina-
tive power.8,12 There are nevertheless limits to forecasting
in personalized medicine which, at the moment, has de-
livered much less than expected.12,13
Although this difficulty of prediction at individual level
is expected based on epidemiological evidence (notably
due to the low discrimination power of most risk markers,
the misleading inference to individuals of observations true
at the group or population level, and the confusion be-
tween causes and risk factors),3 there is a strong resistance
to acknowledge it, nurturing an ever-ending quest to im-
prove individualized prediction to a increasing share of the
population and leading eventually to what we call pseudo-
high-risk prevention strategies.
The pseudo-high-risk prevention strategy
Many clinicians are frustrated with high-risk prevention strat-
egies because the numerous cases emerging from lower risk
strata are not targeted and treated. Furthermore, clinicians
would like to act earlier to prevent patients becoming at high
risk of disease. This is a form of primordial prevention of dis-
ease, applied at a clinical and individual level.14–16
Pharmaceutical companies are also keen to widen the criteria,
to have more people eligible for treatment. Hence, there is ten-
dency to widen the strata of people requiring individual inter-
vention by targeting individuals at intermediate-risk (Figure 1).
This widening is at the core of pseudo-high risk preven-
tion strategies. It is justified by the absence of self-evident
or ‘natural’ thresholds to define high-risk status. Indeed, in
many cases, there is a continuum in the relation between
risk factor and the absolute risk of disease. However, in
many cases, the relation is log-linear.17 Therefore, for an
identical absolute reduction in the risk factor, the resulting
absolute risk of disease reduction will be much smaller for
individuals within the intermediate-risk strata than within
the high-risk strata (Figure 1, panel D). Consequently,
interventions targeting patients at intermediate risk will
have a relatively small (absolute) benefit.
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There are numerous recent examples of widening criteria
to define conditions requiring an individualized intervention.
Hence, in 2003, the Seventh US Joint National Committee
Guidelines defined ‘pre-hypertension’ for blood pressure be-
tween 130 and 139/85 and 89 mmHg, considered as a precur-
sor of hypertension:18 40% of men and 23% of women in
the USA have pre-hypertension, in addition to the 27% of
men and women who have hypertension. Targeting all these
persons for individualized treatment and follow-up is a huge
burden for the healthcare system. Treatment of individuals
with pre-hypertension could delay the occurrence of hyper-
tension, but there is no proof that it would have any true
health benefit such as a reduction of cardiovascular diseases.
More recently, a relative low absolute cardiovascular
risk threshold was recommended to prescribe statins, re-
sulting in 49% of US adults between the age of 45 and 75
becoming eligible for treatment.19 However, it was shown
that the US risk prediction algorithm overestimated the ab-
solute risk.20 Further, these new recommendations put
many primary prevention patients on statin therapy where
there is little trial evidence, and some patients for which
trial evidence exists would not be eligible.19
Another example is pre-diabetes. The diagnosis of this
condition aims to identify individuals at risk of diabetes
and to reduce its occurrence. Pre-diabetes implies a condi-
tion which progresses toward diabetes, although probably
less than half of individuals with pre-diabetes will develop
diabetes later in life.21 Furthermore, there is no evidence
that treatment (either through lifestyle intervention or
medication) of pre-diabetes improves any health outcomes,
besides delaying the occurrence of diabetes. Lowering the
blood glucose threshold to define hyperglycaemic disorders
requiring personalized interventions such as pre-diabetes
can lead to overdiagnosis,21,22 which occurs when individ-
uals are diagnosed with a condition for which there is no
intervention improving substantially the prognosis.23,24
Contrasting with these examples, it is worth mentioning
the ‘polypill’ prevention strategy which is a special case of
high-risk strategies for the prevention of cardiovascular
diseases.10 The idea is to treat with a combination of vari-
ous drugs (notably antihypertensive and statins) all individ-
uals aged 55 years and over or with a personal history of
cardiovascular diseases. The major difference with usual
high-risk prevention strategy is the extreme simplification
of the identification and risk stratification processes.
Hence, it spares resources used for risk assessment and
stratification, and potentially greatly simplifies healthcare
delivery.25 Further, the polypill strategy makes treatment
culturally more appropriate since all individuals 55 years
old and over would be treated. Hence, taking drug treat-
ment for the prevention of cardiovascular diseases would
become a normal health behaviour, which would facilitate
the long-term adherence, as theorized by Rose for other
health behaviours. Such strategy should however not be
considered as a pseudo-high-risk prevention strategy.
Conclusion
Widening the criteria justifying individual preventive inter-
ventions and the related pseudo-high-risk strategies lead to
treat, individually, ever healthier and larger strata of the
population. If the treatments offered are the same as those in
high-risk individuals, the benefit/harm balance of treating
these people will be automatically less favourable. The
pseudo-high-risk prevention strategies raise similar problems
compared with high-risk strategies, however on a larger scale,
and without any of the benefit of population-based strategies.
We have also argued that their strategies have limited poten-
tial to improve individualized prevention and are unable to
reduce the incidence of disease at a population level since
they are not targeting determinants of average risk.
One driver of pseudo-high-risk prevention strategies is
the fact that individual-focused interventions are easier to
test in randomized controlled trials and hence easier to im-
plement on the basis of strength of evidence compared with
population-based intervention. If we want to limit the use
of pseudo-high-risk prevention strategies, more research
and stronger evidence are needed for the implementation
of population-based strategies.
Finally, Rose argued that both high-risk and popula-
tion-based strategies should be applied as they are mutu-
ally supportive, not rivals.2 However, the pseudo-high-risk
strategies are bound to absorb large resources because of
the individual risk assessment and follow-up for a large
share of the population. As such, these preventive strat-
egies compete with other more efficient preventive inter-
ventions, which, in a time of healthcare cost containment
and in low resources settings, is highly problematic.
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